Line design
The court found that defendants had not met their clear-and-convincing burden of proving that formulation and method-of-treatments patents-in-suit were obvious.
GENERICally Speaking: A Hatch Waxman Litigation Bulletin

Case Name: Cephalon, Inc. v. Slayback Pharma Ltd., No. 17-1154-CFC, 2020 WL 1983730 (D. Del. April 27, 2020) (Connolly, J.) 

Drug Product and Patent(s)-in-Suit: Bendeka® (bendamustine hydrochloride); U.S. Patents Nos. 9,265,831 (“the 831 patent”), 9,572,797 (“the 797 patent”), 9,144,568 (“the 568 patent”), 9,597,399 (“the 399 patent”), and 9,572,887 (“the 887 patent”)

Nature of the Case and Issue(s) Presented: Bendeka is indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Prior to trial, Defendants stipulated to infringement. The sole issue at trial concerned the validity of the claims of the patents-in-suit, which the court upheld.

Why Cephalon Prevailed: The court found that the formulation patents were not obvious. The asserted claims in those patents recited a non-aqueous liquid composition that contained: (i) bendamustine (or a pharmaceutically acceptable salt thereof); (ii) about 5% to about 10% by volume of the solvent propylene glycol (PG); (iii) the solvent polyethylene glycol (PEG); (iv) one of the following ratios of PEG to PG: about 95:5, about 90:10, about 85:15, about 80:20, and about 75:25; and (v) a stabilizing amount of an antioxidant. Defendants demonstrated that a POSITA was motivated to develop a non-aqueous liquid bendamustine formulation, but they could not establish that a POSITA would have: (i) used PEG and PG solvents; (ii) achieved the PEG:PG ratios; (iii) picked an antioxidant; (iv) implemented the claimed concentrations of bendamustine; (v) or achieved the PG ester stability limitations recited in the asserted claims. The court found that although the evidence of commercial success did not support a finding of non-obviousness, defendants had not shown by clear and convincing evidence that the prior art would have motivated a POSITA to reach the claimed formulations.

The court also found that the method-of-treatment patents were not obvious. The administration claims recited methods of treating CLL or NHL with a liquid bendamustine composition. The court explained that the prior art would have motivated a POSITA to reach the claimed formulation, dose, and dosing schedule, but that a POSITA would not have been motivated to reach the claimed administration times, volumes, and concentrations. The court further provided that plaintiffs’ secondary indicia of non-obviousness—commercial success, long-felt need, skepticism, and praise—did not support a finding of non-obviousness, but nevertheless found that the prior art would not have motivated a POSITA to arrive at the claimed administrations with a reasonable expectation of success.

Related Attorneys

Related Services

GENERICally Speaking Summer 2020

Jump to Page

Robins Kaplan LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek